|
May 7
|
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
|
|
Apr 29
|
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
|
|
Mar 27
|
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
|
|
Jan 10
|
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
|
|
Aug 9
|
Q2 2023 Atea Pharmaceuticals Inc Earnings Call
|
|
Aug 8
|
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
|